semaglutide weight loss south central indiana 6 weeks in, 15 lbs. down This time I'm not giving up! #fyp #weightloss GLP4 coming out Eli Lilly

The agonist exclusively activates GLP-1R , driving glucose-dependent insulin secretion, delayed gastric emptying, and central satiety signaling (hypothalamic arcuate nucleus)

Figure from Rossing et al NDT 2023 Primary Outcome This was a composite of time of first occurrence of: Onset of kidney failure (persistent eGFR 28 days or initiation of long-term KRT, kidney transplantation) Persistent 50% reduction in eGFR from baseline Death from kidney or CV causes Secondary Outcomes Confirmatory secondary outcomes were analyzed hierarchically

Bray GA, Kim KK, Wilding JPH, World Obesity Federation

Advantage : Neither (tie) Weight Loss Efficacy# MET-097i : Phase 2b VESPER-1 showed up to 14.1% mean placebo-subtracted weight loss after 28 weekly doses

Six of the eleven clinical trials focused on GLP-1 receptor agonists, particularly semaglutidethe active ingredient in medications such as Ozempic and Wegovyand tirzepatide, marketed as Mounjaro